- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Interventions
- Ferumoxytol, MM-398
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 107,141
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastrointestinal Diseases
- Interventions
- Research Registry
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sickle Cell Disease
- Interventions
- Epeleuton
- Drug
- Lead sponsor
- Afimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more
- Conditions
- HIV-1 and Hepatitis C Co-Infection
- Interventions
- pioglitazone, peginterferon, ribavirin
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
- Conditions
- Kidney Disease, Kidney Failure, Chronic Kidney Disease
- Interventions
- Surgical fistula creation from patient's anatomy, Surgical Graft implant
- Procedure · Device
- Lead sponsor
- E. Peden, MD
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HER2+/HR+ Breast Cancer
- Interventions
- ZW25 (Zanidatamab), Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Nashville, Tennessee • Seattle, Washington
- Conditions
- Restless Legs Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2029
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Postural Tachycardia Syndrome (POTS), Vasovagal Syncope (VVS), Fainting
- Interventions
- Northera (Droxidopa), Placebo
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Hawthorne, New York
- Conditions
- Group 2 Pulmonary Hypertension, Heart Failure
- Interventions
- Gradient Denervation System
- Device
- Lead sponsor
- Gradient Denervation Technologies
- Industry
- Eligibility
- 22 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina + 4 more
- Conditions
- BK Virus Infection
- Interventions
- MAU868, Placebo
- Drug · Other
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more
- Conditions
- Depressive Symptoms
- Interventions
- Audio-based behavioral activation intervention, Audio-based self-monitoring intervention
- Device
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Pain, Cannabis, Opioid Use, Unspecified
- Interventions
- Within-subject test of blinded study medications
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epilepsy
- Interventions
- Nelli
- Device
- Lead sponsor
- Neuro Event Labs Inc.
- Industry
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Post Surgical Respiratory Failure, Respiratory Complication
- Interventions
- Linshom Continuous Predictive Respiratory Monitoring
- Device
- Lead sponsor
- Linshom Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Ellicott City, Maryland • Columbus, Ohio
- Conditions
- Plaque Psoriasis
- Interventions
- Roflumilast
- Drug
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Northridge, California • San Diego, California + 16 more
- Conditions
- Obesity, Overweight
- Interventions
- Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide), Placebo II (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 50
- States / cities
- Buena Park, California • Concord, California • Fresno, California + 42 more
- Conditions
- Epileptic Encephalopathy
- Interventions
- S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
- Conditions
- DYT-1, Dystonia
- Interventions
- Ampicillin, Sugar pill
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 7 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
- Conditions
- Diabetes, Glucose Variability, CGM
- Interventions
- CGM System for Type 1 and Type 2 Diabetes Mellitus
- Device
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Head and Neck Cancer, Pain, Lung Cancer, Esophageal Cancer
- Interventions
- Telephone-Based Intervention, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 478 participants
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey